Beam Therapeutics
Update in progressBEAM (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Beam Therapeutics is a Cambridge, Massachusetts biotech company focused on precision genetic medicines for serious diseases. Its programs include an autologous hematopoietic stem cell therapy for sickle cell disease, BEAM-302 and BEAM-304 liver-targeting lipid nanoparticles for alpha-1 antitrypsin deficiency and phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. It develops the ESCAPE platform with antibody conditioning and edited HSCs, and BEAM-103, an anti-CD117 antibody. Partnerships include Pfizer, Verve Therapeutics, and Orbital Therapeutics.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.38
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. John M. Evans M.B.A.
- Founded2017
- Employees540
- Websitebeamtx.com
Identifiers
- ISINUS07373V1052
- FIGIBBG00KXC8646
- CUSIP07373V105
- CIK0001745999